Clinical Social Workers in Findlay, OH Accepting Medicare

49 Clinical Social Workers found. Showing 41 - 49

Hilary Neff Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1624 Tiffin Ave Ste D, Findlay, OH 45840 Phone: 419-422-7800

Pam Oliver, LISW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1918 N Main St, Findlay, OH 45840 Phone: 419-425-5050    Fax: 419-423-6464

Elana Rochelle Hoffman-cooper, LISW-SUP Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1800 N Blanchard St, Findlay, OH 45840 Phone: 419-420-8461

Sara Wagner, LPC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1918 N Main St, Findlay, OH 45840 Phone: 419-425-5050    Fax: 419-423-6464

Francesca A Leass, LISW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 11745 Township Road 145, Findlay, OH 45840 Phone: 419-999-2010    Fax: 419-999-6284

Rachael Helms, LISW-S Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 206 W Lima St, Findlay, OH 45840 Phone: 419-344-7334

Sandra Kay Vent, LISW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 1610 Fostoria Ave, Findlay, OH 45840 Phone: 419-429-6480    Fax: 419-429-6481

Chelsea Snodgrass, BSSW, LSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1624 Tiffin Ave, Findlay, OH 45840 Phone: 419-427-3320

Brent Johnson, LSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1918 N Main St, Findlay, OH 45840 Phone: 419-425-5050    Fax: 419-423-7854

News Archive

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo

Research examines link between opioid suppression of immune system and cancer recurrence

​The methods used to anesthetize prostate cancer patients and control pain when their prostate glands are surgically removed for adenocarcinoma may affect their long-term cancer outcomes, a study led by Mayo Clinic has found.

BIDMC investigators develop three-minute assessment that identifies delirium in older hospital patients

Delirium is a state of confusion that develops suddenly, often following an acute medical illness, a surgical procedure or a hospitalization. Although delirium is estimated to complicate hospital stays for over 2.5 million elderly individuals in the U.S. each year, this common condition often goes undetected. The end result can be serious complications with sometimes devastating consequences for vulnerable hospitalized elders.

FDA approves Strattera for ADHD in children and adolescents

Eli Lilly and Company announced today that the United States Food and Drug Administration (FDA) has approved Strattera (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.

Read more Medical News

› Verified 4 days ago

• 1
• 2
• 3(current)